Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ENSCW | 8-K | bearish | 7/10 | Ensysce Biosciences reported Q1 2026 results with a net loss of $3.6M, widening from a $1.9M loss in Q1 2025, driven by | May 15, 2026 |
| BNTX | 6-K | neutral | 4/10 | BioNTech held its 2026 Annual General Meeting, where all agenda items were approved by shareholders, including expanding | May 15, 2026 |
| RAJAF | 20-F | bearish | 6/10 | Cordyceps Sunshine Biotech Holdings Co., Ltd. filed its Form 20-F annual report for FY2025, reporting a net loss of $154 | May 15, 2026 |
| ENLV | 6-K | bearish | 6/10 | Enlivex received a Nasdaq minimum bid price deficiency notice because its ordinary shares closed below $1.00 for 30 cons | May 15, 2026 |
| AVXL | 8-K | neutral | 2/10 | Anavex Life Sciences Corp. disclosed the departure of COO Felix Lauscher on May 11, 2026, as part of a broader reorganiz | May 15, 2026 |
| ANAB | 144 | neutral | 3/10 | Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 on May 15, 2026, indicating intent to sell 10,000 shares of co | May 15, 2026 |
| KPTI | CLUSTER | bearish | 6/10 | Six Karyopharm executives, including the CEO and C-suite, sold a total of $35K in open-market shares on May 14, 2026, on | May 15, 2026 |
| INSM | CLUSTER | neutral | 3/10 | Two C-suite insiders (CMO and CLO) sold a total of ~$981K worth of INSM shares, representing a trivial 0.004% of the $25 | May 15, 2026 |
| VCEL | CLUSTER | neutral | 2/10 | Vericel Corp insiders sold ~$459K in open-market transactions over the past week, representing a trivial 0.027% of the $ | May 15, 2026 |
| KPTI | CLUSTER | neutral | 3/10 | Five Karyopharm insiders, including the CEO and C-suite, sold a total of $31K in open-market sales on May 14, 2026, the | May 15, 2026 |
| LTRN | 8-K | mixed | 6/10 | Lantern Pharma reported Q1 2026 net loss of $3.3M ($0.30/share), a 27% YoY improvement from $4.5M ($0.42), driven by 47% | May 15, 2026 |
| KPTI | CLUSTER | bearish | 6/10 | Karyopharm's CEO, CAO, and EVP/CLO sold a total of $23K in open-market shares on May 14, 2026, the same day the company | May 15, 2026 |
| RANI | PRESS-RELEASE | bullish | 5/10 | Rani Therapeutics reported Q1 2026 GAAP EPS of -$0.04, beating consensus of -$0.06 by 33%, with contract revenue rising | May 15, 2026 |
| PSTV | PRESS-RELEASE | bearish | 6/10 | Plus Therapeutics reported Q1 2026 EPS of -$1.05, a 19.2% miss vs consensus of -$0.87, on revenue of $1.0M (grant + CNSi | May 15, 2026 |
| CADL | PRESS-RELEASE | bullish | 8/10 | Candel Therapeutics announced extended follow-up data from the phase 3 trial of aglatimagene (CAN-2409) in localized pro | May 15, 2026 |
| OTLK | PRESS-RELEASE | bearish | 6/10 | Outlook Therapeutics reported Q2 FY2026 results with GAAP net loss of $0.05/share (vs consensus $-0.12) and adjusted net | May 15, 2026 |
| CCCC | 8-K | neutral | 2/10 | C4 Therapeutics disclosed the departure of Chief Accounting Officer Mark Mossler, effective May 15, 2026, with no disagr | May 15, 2026 |
| CDTTW | 8-K | neutral | 3/10 | CDT Equity Inc. entered temporary amendments to its equity line of credit and convertible note, capping regular ELOC pur | May 15, 2026 |
| INDV | 8-K | neutral | 3/10 | Indivior eliminated the Chief Scientific Officer position effective June 1, 2026, with Dr. Christian Heidbreder transiti | May 15, 2026 |
| ADXN | 20-F | bearish | 7/10 | Addex Therapeutics filed its FY2025 20-F annual report, reporting a net loss from continuing operations of CHF 6.8M (vs | May 15, 2026 |
| ANVS | 8-K | mixed | 5/10 | Annovis Bio reported Q1 2026 results showing increased net loss per share ($0.63 vs $0.32) and cash burn, but highlighte | May 15, 2026 |
| ARTL | 8-K | neutral | 3/10 | Artelo Biosciences terminated its At-The-Market Offering Agreement with R.F. Lafferty, which had allowed up to $6.5M in | May 15, 2026 |
| SKYE | 8-K | bearish | 7/10 | Skye Bioscience received a Nasdaq delisting notice on May 13, 2026, for failing to meet the $10M minimum stockholders' e | May 15, 2026 |
| RDY | 6-K | bullish | 6/10 | Dr. Reddy's launched its generic Semaglutide Injection in Canada on May 15, 2026, following Health Canada approval on Ap | May 15, 2026 |
| REGN | PRESS-RELEASE | neutral | 2/10 | Regeneron announced the winners of its 2026 International Science and Engineering Fair (ISEF), awarding over $7 million | May 15, 2026 |
| GIKLY | 6-K | neutral | 3/10 | Grifols filed a 6-K on May 15, 2026, calling an Ordinary General Shareholders' Meeting for June 17-18, 2026. The agenda | May 15, 2026 |
| TVTX | 144 | neutral | 2/10 | Director Timothy Coughlin filed a Form 144 notice to sell 3,250 shares of Travere Therapeutics (TVTX) valued at approxim | May 15, 2026 |
| PROK | 8-K | neutral | 4/10 | ProKidney reported Q1 2026 financial results that were in line with consensus, with a net loss of $20.0M available to Cl | May 15, 2026 |
| PROK | PRESS-RELEASE | neutral | 5/10 | ProKidney reported Q1 2026 EPS of -$0.14, essentially in line with the -$0.14 consensus (a 1.8% miss), with negligible r | May 15, 2026 |
| QUCY | PRESS-RELEASE | neutral | 2/10 | Quantum Cyber announced the launch of a new corporate website at quantum-cyber.ai, positioning itself as an AI-powered, | May 15, 2026 |